Summary:
In 1,879 adults with type 2 diabetes participating in the SURPASS-2 phase 3 trial conducted across 128 sites in 8 countries, once-weekly subcutaneous tirzepatide at doses of 5 mg, 10 mg, or 15 mg for 40 weeks significantly improved markers of β-cell function, insulin sensitivity, and fasting biomarkers, with greater reductions in HbA1c and weight compared to semaglutide 1 mg administered weekly under similar trial conditions for 40 weeks. Efficacy of tirzepatide was consistent regardless of baseline β-cell function and insulin resistance.
| PICO | Description |
|---|---|
| Population | A total of 1,879 adult participants with type 2 diabetes who were part of the SURPASS-2 phase 3 trial conducted across 128 sites in 8 countries. |
| Intervention | Once-weekly subcutaneous tirzepatide administered at doses of 5 mg, 10 mg, or 15 mg for a duration of 40 weeks. |
| Comparison | Semaglutide 1 mg administered weekly as a comparator under similar trial conditions for 40 weeks. |
| Outcome | Tirzepatide demonstrated significantly greater improvements compared to semaglutide in markers of β-cell function, insulin sensitivity, and fasting biomarkers. Reductions in HbA1c and weight were consistently greater with tirzepatide regardless of baseline β-cell function and insulin resistance. |
Source: Frias, Juan P., et al. “Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).” J Clin Endocrinol Metab, 2024. Read article here.
